Clinical Care Options Oncology - Truth and Consequences: Antiangiogenic Therapies in Cancer

.

CCO Treatment Updates Truth and Consequences: Antiangiogenic Therapies in Cancer Virtual Presentation Truth and Consequences: Antiangiogenic Therapies in Cancer Faculty: Robert S. Kerbel, PhD Release Date: July 02, 2010 Expiration Date: July 01, 2011 Robert S. Kerbel, PhD, reviews the latest preclinical and clinical findings on the use of angiogenesis inhibitors to treat cancer, including mechanisms of resistance, the relevance of tumor flare-up after discontinuation of antiangiogenic therapy, and potential markers to predict clinical benefit. Learning Objectives Upon completion of this activity, participants should be able to: Describe the mechanisms of targeting angiogenesis Explain the mechanisms of resistance to antiangiogenic drugs Describe the phenomenon of rebound or tumor flare that may result from the discontinuation of antiangiogenic therapy Evaluate data supporting the use of angiogenesis inhibitors in the neoadjuvant, adjuvant, and metastatic settings Assess the potential clinical role of biomarkers of response to antiangiogenic therapy Truth and Consequences: Antiangiogenic Therapies in Cancer Download slides on the latest preclinical and clinical findings on the use of angiogenesis inhibitors to treat cancer, including mechanisms of resistance, the relevance of tumor flare-up after discontinuation of antiangiogenic therapy, and potential markers to predict clinical benefit. Format: Microsoft PowerPoint (.ppt) | File size: 8.61 MB | Date posted: 7/2/2010 . Jointly Sponsored by USF Health and Clinical Care Options, LLC.